GlassScriptPhysician profile
Joseph Hsiao
NPI 1699139287
$1,752.35
in general payments reported to CMS, 2019-2025
20 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2022: $249 · 2023: $482 · 2024: $410 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $333.55 | 2022-2023 | Dexcom G6 Transmitter |
| Alcon Vision LLC | $255.98 | 2019 | |
| Novo Nordisk INC | $245.43 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Insulet Corporation | $164.95 | 2022-2025 | Omnipod |
| Lilly USA, LLC | $158.96 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $115.00 | 2023 | |
| Radius Health, INC. | $103.48 | 2023-2024 | Tymlos |
| Recordati_rare_diseases_inc. | $63.35 | 2025 | Isturisa |
| Mannkind Corporation | $53.34 | 2023-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $46.88 | 2024 | Recorlev |
| Beta Bionics, INC. | $32.89 | 2023-2024 | Ilet Bionic Pancreas |
| Sanofi-Aventis U.S. LLC | $31.56 | 2025 | |
| Abbott Laboratories | $29.00 | 2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $17.94 | 2024 | Shingrix, Arexvy |
| Embecta Corp. | $17.93 | 2024 | Bd Nano 2nd Gen Pen Needle |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.60 | 2025 | |
| Tandem Diabetes Care, INC. | $16.97 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $16.93 | 2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $15.80 | 2023 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Medtronic, INC. | $14.81 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Hsiao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.